Research programme: methionine aminopeptidase inhibitors - Zafgen

Drug Profile

Research programme: methionine aminopeptidase inhibitors - Zafgen

Alternative Names: ZGN 1258; ZGN 839; ZGN-201

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zafgen
  • Class Small molecules
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Non-alcoholic steatohepatitis; Obesity; Prader-Willi syndrome

Most Recent Events

  • 09 May 2018 Zafgen intends to initiate IND-enabling studies for non-alcoholic steatohepatitis (NASH) (Zafgen pipeline May,
  • 08 May 2018 Zafgen plans a phase I trial of ZGN 1258 for Prader-Willi Syndrome in the fourth quarter of 2018
  • 06 Mar 2018 Zafgen initiated IND enabling studies for ZGN 1258 in Q1 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top